Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines.
Multidrug resistance is frequently found in patients affected by hematological malignancies and has been related to a poor prognosis of acute leukemia. In the present paper we report results concerning the activity of idarubicin, an anthracycline derivative, on the leukemic P388 and P388 doxorubicin-resistant cell lines. The results clearly show that idarubicin inhibits DNA synthesis in the resistant cell line more actively than doxorubicin.
Petrini
M
M
Hematology Department, University of Pisa, Italy.
Mattii
L
L
Valentini
P
P
Sabbatini
A R
AR
Grassi
B
B
Grandi
M
M
D000818:Animals; D004247:DNA / Q000096:biosynthesis; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance; D015255:Idarubicin / Q000494:pharmacology*; D007942:Leukemia, Experimental / Q000378:metabolism; D051379:Mice; D013936:Thymidine / Q000378:metabolism; D014316:Tritium; D014407:Tumor Cells, Cultured
D014316:Tritium; D004317:Doxorubicin; D004247:DNA; D013936:Thymidine; D015255:Idarubicin